NeuroOne to Present at Planet MicroCap Las Vegas 2026 Conference, Highlighting OneRF Platform Progress

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on neurological disorders, announced its participation in the upcoming Planet MicroCap Las Vegas 2026 Conference, scheduled for June 17-18, 2026. The company’s President and CEO, Dave Rosa, will host one-on-one meetings with institutional investors and deliver a presentation on Wednesday, June 17, 2026, at 12:00 p.m. Pacific Time in TRACK 6 - Raphael 3. The presentation will include commercialization updates and anticipated milestones for the OneRF® platform, which targets treatment of the brain, pain, and advanced drug delivery.

In addition to the live presentation, Mr. Rosa participated in a CEO interview with Planet MicroCap host Robert Kraft ahead of the conference, which can be viewed here. The company’s participation in the conference underscores its strategy to engage with the investment community as it progresses toward broader commercialization of its product portfolio.

NeuroOne markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System for the brain, and OneRF® Trigeminal Nerve Ablation System. These solutions are designed to reduce hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering both diagnostic and therapeutic functions. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.

The OneRF platform represents a key growth driver for NeuroOne, as it expands the company’s reach beyond diagnostic electrodes into therapeutic ablation and potential drug delivery applications. The upcoming presentation at the Planet MicroCap conference is expected to provide investors with insight into recent commercial traction and upcoming milestones, including regulatory and clinical developments.

For more information on the conference or to schedule a meeting with management, interested parties can contact the conference representative or email NMTC@mzgroup.us or call Chris Tyson at (949) 491-8235. The webcast of the presentation will be available here, and the conference website can be accessed here.

NeuroOne’s continued presence at investor conferences signals its commitment to building shareholder value as it advances its pipeline and commercializes its FDA-cleared products. The company’s focus on neurological disorders positions it in a growing market with significant unmet need, and the upcoming updates could provide clarity on its path to revenue growth and market expansion.